Aptose Biosciences (TSE:APS) Reaches New 52-Week Low – Should You Sell?

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.98 and last traded at C$2.50, with a volume of 27932 shares changing hands. The stock had previously closed at C$4.56.

Analyst Ratings Changes

Separately, Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th.

Aptose Biosciences Price Performance

The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The company has a market capitalization of C$152.86 million, a P/E ratio of -0.71 and a beta of 1.36. The company has a 50 day moving average price of C$6.25 and a 200 day moving average price of C$10.28.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.